The Brief

Researchers from the University of Minnesota and Queensland Brain Institute have found that brain and blood cells in young adults with major depressive disorder overproduce ATP — the body’s core energy molecule — at rest, but cannot increase output when placed under stress. The study, published in Translational Psychiatry, is the first to identify matching cellular energy dysfunction in both the brain and bloodstream of people with depression, raising the prospect of blood-based diagnostic tools.

The Report

A study of 25 young adults has identified a distinctive pattern of cellular energy dysfunction in people with major depressive disorder — one that appears simultaneously in brain tissue and in blood cells, and that correlates directly with the severity of their fatigue.

The research team, led by Dr. Kathryn Cullen at the University of Minnesota, collected brain scans and blood samples from participants aged 18 to 25, split between those diagnosed with MDD and healthy controls. Analysis was carried out by Associate Professor Susannah Tye and Dr. Roger Varela at the Queensland Brain Institute. Using 7-Tesla magnetic resonance spectroscopy — an advanced imaging technique developed at the University of Minnesota’s Center for Magnetic Resonance Research — the team measured ATP production rates in the visual cortex. Blood cells were tested separately, at rest and after mitochondrial stress was chemically induced.

The results ran counter to expectation. Prior research had associated depression with lower-than-normal energy production. This study found the opposite at baseline: cells in the MDD group produced more ATP at rest than those of healthy controls. The higher resting output correlated positively with scores on the Fatigue Severity Scale. Under stress, however, the pattern reversed — blood cells in the depressed group showed markedly less capacity to increase ATP production than those of controls.

“This was surprising, because you might expect energy production in cells would be lower for people with depression,” Dr. Varela said. “It suggests that in the early stages of depression, the mitochondria in the brain and body have a reduced capacity to cope with higher energy demand, which may contribute to low mood, reduced motivation and slower cognitive function.”

The researchers describe the finding as the first identification of matching ATP patterns in both brain and blood cells of young people with MDD — a parallel that could eventually support diagnostic blood tests, moving depression assessment from subjective questionnaires toward measurable biological markers. Associate Professor Tye noted that her team has already begun assessing mitochondrial activity before and after treatment in human samples, with the aim of developing a test to predict patient response to different antidepressants.

The study used a small sample — 18 participants with usable imaging data and 24 with usable blood data — and was limited to young adults in early-stage depression. Whether the same ATP signature holds in older populations or in chronic, treatment-resistant cases remains untested. Depression currently affects an estimated 47.8 million Americans, with prevalence among 18-to-29-year-olds having doubled over the past eight years to 26.7 percent. The NIH and the University of Minnesota Wallin Neuroscience Discovery Fund funded the research.

The Angle

The counterintuitive finding is the part worth paying attention to. Depression research has spent decades working from the assumption that a disease characterised by exhaustion would show diminished cellular energy. What this study describes is something structurally different — an engine running too hot at idle, with nothing left when the accelerator is pressed. That distinction matters because it suggests the problem is not a deficit in production but a failure of regulation, and those are different engineering problems with different solutions.

What makes the study more interesting than the sample size strictly warrants is the parallel between brain and blood. If the same ATP signature is detectable in a routine blood draw as in a 7-Tesla brain scan, then the distance between a proof-of-concept finding and a clinical diagnostic tool is shorter than it usually is in psychiatric research. Depression has been diagnosed by questionnaire for decades — a method that relies on the patient’s ability to accurately report subjective experience of a condition whose defining feature is distorted cognition. A biological marker does not fix that entirely. But it changes which questions are answerable.

The broader pattern here is one worth watching. Tye’s prior work linked peripheral inflammation to disrupted dopamine synthesis in the brain. This study extends the connection to mitochondrial energy metabolism. What is emerging, piece by piece, is a picture of depression as a systemic metabolic condition that happens to express itself in mood — rather than a mood disorder that happens to have metabolic correlates. That reframing, if it holds, does not just change how depression is treated. It changes what depression is.